预约演示

更新于：2026-07-20

Paclitaxel

紫杉醇

更新于：2026-07-20

概要

基本信息

药物类型

小分子化药

别名

EmPAC、LDE-paclitaxel、NanoPac

+ [78]

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤感染消化系统疾病+ [12]

在研适应症

晚期胃癌转移性胰腺腺癌转移性乳腺癌+ [212]

非在研适应症

异戊酸血症急性淋巴细胞白血病食管腺癌+ [206]

原研机构

National Institutes of Health

在研机构

National Cancer Institute

NRG Oncology

The University of Texas MD Anderson Cancer Center

+ [52]

非在研机构

Radiation Therapy Oncology Group

Vivesto ABHoffmann-La Roche, Inc.

+ [53]

权益机构

深圳市康哲药业有限公司

沈阳三生制药有限责任公司

Hanmi Pharmaceutical Co., Ltd.

+ [26]

最高研发阶段批准上市

首次获批日期

美国 (1992-12-29),

艾滋病相关性卡波西肉瘤乳腺癌卵巢癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C47H51NO14

InChIKeyRCINICONZNJXQF-MZXODVADSA-N

CAS号33069-62-4

关联

2,691

项与紫杉醇相关的临床试验

NCT07594548

/ Not yet recruiting临床1期IIT

A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving futibatinib with paclitaxel and ramucirumab may be safe and tolerable in treating patients with locally advanced or unresectable gastric, gastroesophageal junction or esophageal adenocarcinoma.

开始日期2027-09-09

申办/合作机构

Northwestern University

[+1]

NCT07346196

/ Not yet recruiting临床2期IIT

A Randomized Phase II Trial of Induction Cemiplimab Plus Chemotherapy With or Without Fianlimab in Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.

开始日期2027-02-07

申办/合作机构

The University of Chicago

NCT07281417

/ Recruiting临床2期IIT

Neoadjuvant Chemotherapy With or Without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study

This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.

开始日期2026-11-24

申办/合作机构

National Cancer Institute

100 项与紫杉醇相关的临床结果

登录后查看更多信息

100 项与紫杉醇相关的转化医学

登录后查看更多信息

100 项与紫杉醇相关的专利（医药）

登录后查看更多信息

52,845

项与紫杉醇相关的文献（医药）

2026-12-31·Future Science OA

Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer

Article

作者: Su, Zhimin ; Li, Zhiyong ; Shen, Feng ; Jiang, Jiana

OBJECTIVE:

We aim to compare the clinical efficacy and safety of albumin-bound paclitaxel (nab-PTX) (125 mg/m2, q2w) for two weeks and (125 mg/m2, d1, d8, q3w) for three weeks in the first-line treatment of advanced pancreatic cancer.

METHODS:

The medical records of patients with advanced pancreatic cancer who received nab-PTX for 2 weeks and 3 weeks, combined with gemcitabine, from July 2018 to January 2023, were retrospectively analyzed. The efficacy and adverse reactions of the two groups of patients were compared.

RESULT:

A total of 64 patients were included. The median progression-free survival (mPFS) of the 2-week group was 5.6 months, while the 3-week group was 7.8 months. The median overall survival (mOS) of the 2-week group was 14.0 months, while the 3-week group was 14.7 months. The multivariate analysis showed that a physical fitness status score of 0-1 was an independent factor with better OS, while metastatic sites ≥ 3 were related to poor OS. The incidence of leukopenia or neutropenia, neurotoxicity, fatigue, and poor appetite in the 2-week group was lower than that in the 3-week group.

CONCLUSION:

The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

2026-12-31·ANNALS OF MEDICINE

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials

Review

作者: Du, Zhiyan ; Xu, Yixin ; Wang, ZhiLong ; Fan, Chao ; Jiang, Zhihui ; Wu, Tingting ; Zheng, Yingying ; Lv, Mingming ; Adilijiang, Adilai. ; Pan, Ying ; Bai, Bingxin ; Deng, Changjiang ; Xie, Xiang

BACKGROUND:

Coronary small-vessel disease (SVD) remains challenging for percutaneous coronary intervention (PCI) because small lumens magnify restenosis and ischemic risk. Multiple devices are available, yet their comparative performance is uncertain. This study evaluated and ranked PCI strategies for SVD.

METHODS:

A systematic review and network meta-analysis was conducted in accordance with PRISMA. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar were searched from inception to 15 August 2025. Eligible studies were English-language randomized controlled trials enrolling adults with angiographic SVD defined as reference vessel diameter ≤3.0 mm, comparing PCI strategies, and reporting target lesion revascularization (TLR), binary restenosis (BR), or myocardial infarction (MI). A frequentist random-effects network meta-analysis generated odds ratios (ORs) with 95% confidence intervals (CIs) and treatment rankings using the surface under the cumulative ranking curve (SUCRA).

RESULTS:

Thirty-nine trials including 14,503 patients met the criteria. For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). For BR (32; 6,468), SES, ZES, and paclitaxel-coated balloons (DCB-PTX) ranked highest (95.0%, 80.0%, and 78.3%). For MI (37; 11,602), SES, DCB-PTX, and ZES ranked highest (79.0%, 78.7%, and 68.5%). Representative effects showed SES reduced TLR versus bare-metal stents (BMS) (OR, 0.25; 95% CI, 0.15-0.43) and MI versus BMS (OR, 0.41; 95% CI, 0.21-0.79). Conventional approaches such as BMS, plain old balloon angioplasty (POBA), and gold-plated balloon angioplasty (GPBA) ranked lowest across outcomes.

CONCLUSION:

SES provides the most consistent clinical benefit for coronary SVD. ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD.

6,986

项与紫杉醇相关的新闻（医药）

20 小时之前

·ioncology

ESMO 2026丨瞭望前瞻，百余项中国乳腺癌研究亮相ESMO，一文速览

点击蓝字，关注我们编者按：2026年欧洲肿瘤内科学会年会（ESMO 2026）将于10月23日至27日在西班牙马德里召开。作为全球肿瘤领域最具影响力的年度盛会之一，ESMO每年覆盖基础研究、转化医学与临床诊疗全维度前沿进展，是国际肿瘤学界交流学术成果、更新诊疗理念的核心平台。目前，ESMO官网已公布部分摘要标题，《肿瘤瞭望》特针对乳腺癌领域的中国入选研究进行系统梳理，供读者提前把握本次大会的中国学术动态。（由于目前多数研究摘要全文尚未正式发布，本次整理仅基于已公开的标题信息，如有疏漏或表述偏差，敬请留言指正。）快速口头报告摘要号：4RO 英文标题：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial 中文标题：转移性乳腺癌ADC经治后采用同载荷异载荷新型ADC的靶点转换研究：一项前瞻性、开放标签的 II 期平台试验（SWITCH）讲者：刘西禹 (复旦大学附属肿瘤医院) 摘要号：5RO 英文标题：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer 中文标题：新型靶向B7-H3 ADC SYS6043治疗晚期乳腺癌的安全性与有效性讲者：王红霞 (复旦大学附属肿瘤医院) 摘要号：4639RO 英文标题：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01 中文标题：芦康沙妥珠单抗对比化疗用于既往经治局部复发或转移性三阴性乳腺癌的III期OptiTROP-Breast01研究最终OS分析讲者：樊英 (中国医学科学院肿瘤医院) 摘要号：4640RO 英文标题：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study 中文标题：新型靶向Nectin-4 ADC bulumtatug Fuvedotin（BFv，9MW2821）在既往接受过拓扑异构酶I抑制剂为基础的ADC治疗的局部晚期或转移性三阴性乳腺癌（la/mTNBC）患者中显示出显著疗效：一项II期临床研究的结果讲者：张剑 (复旦大学附属肿瘤医院) 壁报 Basic science（基础科学）摘要号：399P 英文标题：C15orf48 drives breast cancer liver metastasis via glutathione dependent activation of Wnt/β-catenin signaling 中文标题：C15orf48通过谷胱甘肽依赖性激活Wnt/β-catenin信号通路驱动乳腺癌肝转移讲者：宋振川（河北医科大学第四医院） Advanced breast cancer, other（晚期乳腺癌，其他）摘要号：6P 英文标题：Machine learning model based on pathomics features predicts T-DXd response in advanced breast cancer 中文标题：基于病理组学特征的机器学习模型可预测晚期乳腺癌对T-DXd治疗的反应讲者：刘月平（河北医科大学第四医院）摘要号：10P 英文标题：A randomized phase 3 study of disitamab vedotin (DV) versus chemotherapy (chemo) in HER2-low advanced breast cancer: overall and the liver metastasis (BCLM) subgroup results 中文标题：维迪西妥单抗对比化疗治疗HER2低表达晚期乳腺癌的随机III期研究：总体及肝转移亚组结果讲者：王佳玉（中国医学科学院肿瘤医院）摘要号：19P 英文标题：Ribociclib plus endocrine therapy versus chemotherapy in patients with rapidly progressive HR+/HER2− advanced breast cancer: a multicenter phase II study with external controls 中文标题：瑞波西利联合内分泌治疗对比化疗用于快速进展HR+/HER2−晚期乳腺癌：一项多中心II期研究及外部对照讲者：Min Tian (Nanjing, China) 摘要号：26P 英文标题：Efficacy and Safety of Anlotinib-Based Therapy in Advanced Breast Cancer: A Real-World Study 中文标题：以安罗替尼为基础方案治疗晚期乳腺癌的真实世界疗效与安全性研究讲者：姚静（华中科技大学同济医学院附属协和医院）摘要号：27P 英文标题：Local treatment in metastatic breast cancer with oligoprogression: a retrospective cohort study and reconstructive individual patient data meta-analysis 中文标题：寡进展转移性乳腺癌的局部治疗：回顾性队列研究与重建个体患者数据荟萃分析讲者：Haoting Shi (Shanghai, China) 摘要号：73eP 英文标题：Chidamide combined with Vinorelbine and Capecitabine for HER2-Negative Advanced Breast Cancer: A Single-Arm, Single-Center, Phase II Clinical Trial 中文标题：西达本胺联合长春瑞滨和卡培他滨治疗HER2阴性晚期乳腺癌：一项单臂、单中心II期临床试验讲者：La Zou (Chongqing, China) 摘要号：74eP 英文标题：Intraventricular thiotepa in combination with methotrexate for leptomeningeal metastasis from breast cancer (NJMU-BC04): a single-arm phase II study 中文标题：脑室内注射塞替哌联合甲氨蝶呤治疗乳腺癌软脑膜转移（NJMU-BC04）：一项单臂II期研究讲者：Mengyao Zha (Nanjing, China) 摘要号：79eP 英文标题：Eribulin After Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Real-World Multicenter Retrospective Study 中文标题：抗体偶联药物治疗后应用艾立布林治疗转移性乳腺癌：一项真实世界多中心回顾性研究讲者：邵彬（北京大学肿瘤医院）摘要号：83eP 英文标题：An EGFR dominating triple positive tumor clone engages cycling M2 macrophages during disease progression following bispecific HER3/EGFR antibody-drug conjugate (ADC) treatment in metastatic breast cancer 中文标题：EGFR主导的三阳性肿瘤克隆在转移性乳腺癌双特异性HER3/EGFR ADC治疗后疾病进展中招募循环M2巨噬细胞讲者：吕铮（吉林大学第一医院）摘要号：96eP 英文标题：Real-world effectiveness of antibody-drug conjugates versus conventional systemic therapies in metastatic breast cancer: An inverse probability of treatment weighting analysis 抗体偶联药物对比传统全身治疗在转移性乳腺癌中的真实世界疗效：逆概率处理加权分析讲者：Shukai Guo (Fuzhou, China) Breast cancer, early stage（早期乳腺癌）摘要号：547P 英文标题：Predictive Role of ctDNA for Pseudoprogression in Triple-Negative Breast Cancer during Neoadjuvant Immunotherapy 中文标题：ctDNA在三阴性乳腺癌新辅助免疫治疗期间假性进展的预测作用讲者：王永胜（山东省肿瘤医院）摘要号：560P 英文标题：Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study 中文标题：吡咯替尼联合曲妥珠单抗和芳香化酶抑制剂新辅助治疗HR+/HER2+乳腺癌：一项单臂、多中心II期探索性研究讲者：葛洁（天津医科大学肿瘤医院）摘要号：570P 英文标题：Qualitative synergism between female hormone use and secondhand smoke on breast carcinogenesis: A prospective cohort study 中文标题：雌激素使用与二手烟在乳腺癌发生中的定性协同作用：一项前瞻性队列研究讲者：Hong-Hong Zhu (Quzhou, China) 摘要号：580P 英文标题：Ki-67-Guided Stratification and Resistance Mechanism Analysis of CDK4/6 Inhibitor Therapy Following Adaptive Neoadjuvant Endocrine Treatment in HR+/HER2− Breast Cancer 中文标题：HR+/HER2-乳腺癌中适应性新辅助内分泌治疗后CDK4/6抑制剂治疗的Ki-67引导分层与耐药机制分析讲者：王永胜（山东省肿瘤医院）摘要号：616eP 英文标题：Radiotherapy-Integrated Neoadjuvant Therapy Deepens Response and Expands Eligibility for Surgery Omission in TNBC and HR-/HER2+ Breast Cancer: Interim Analysis of a Multicenter Phase II Study 中文标题：放疗联合新辅助治疗可增强对TNBC和HR-/HER2+乳腺癌的疗效，并扩大免手术治疗发适应证：一项多中心II期研究期中分析讲者：杨正军（天津医科大学肿瘤医院）摘要号：617eP 英文标题：Ultrasound-Guided Vacuum-Assisted Excision Followed by Definitive Surgery in Early-Stage Small Breast Cancer: A Single-Arm Trial 中文标题：超声引导下真空辅助旋切术后续根治性手术治疗早期小乳腺癌：一项单臂试验讲者：Siyuan Wang (Xi'an, China) 摘要号：628eP 英文标题：Extended Sentinel Lymph Node Biopsy Using a Single Tracer After Neoadjuvant Therapy for Breast Cancer: A Retrospective Real-World Study 中文标题：乳腺癌新辅助治疗后应用单一示踪剂的扩展前哨淋巴结活检：一项回顾性真实世界研究讲者：张聚良（空军军医大学西京医院）摘要号：635eP 英文标题：Profound Vitamin D Deficiency Identifies Elevated Heart Failure Risk Among Breast Cancer Survivors: A UK Biobank Multi-State Analysis 中文标题：重度维生素D缺乏识别乳腺癌幸存者中升高的心力衰竭风险：一项UK Biobank多状态分析讲者：Yiyin Zhang (Beijing, China) 摘要号：636eP 英文标题：A novel single-molecule dual CDK4/CDK2 inhibitor series with cytotoxic cellular activity and improved kinome selectivity for HR+/HER2− breast cancer and CCNE1-amplified ovarian cancer 中文标题：新型单分子双靶点CDK4/CDK2抑制剂系列：针对HR+/HER2−乳腺癌和CCNE1扩增卵巢癌具有细胞毒活性和改善的激酶组选择性讲者：Xianqiang Sun (Shanghai, China) 摘要号：639eP 英文标题：Carbon Nano-Lymph Tracer in Modified Radical Mastectomy After Neoadjuvant Chemotherapy for Breast Cancer 中文标题：纳米碳淋巴示踪剂在乳腺癌新辅助化疗后改良根治术中的应用讲者：Feng Liu (Fuyang, China, Anhui) 摘要号：646eP 英文标题：Patient and Oncologist Preferences Regarding CDK4/6 Inhibitor Adjuvant Therapy for HR+/HER2- Early Breast Cancer in China 中文标题：中国HR+/HER2−早期乳腺癌患者与肿瘤科医生对CDK4/6抑制剂辅助治疗的偏好讲者：郝春芳（天津医科大学肿瘤医院）摘要号：648eP 英文标题：Standard imaging-guided, Doppler-free chest wall perforator flap reconstruction for granulomatous lobular mastitis: A simplified approach for resource-limited settings 中文标题：标准影像引导下，无多普勒胸壁穿支皮瓣重建术治疗肉芽肿性小叶性乳腺炎：面向资源有限地区的简化方案讲者：王子莹（常州市第一人民医院） HER2+ breast cancer（HER2阳性乳腺癌）摘要号：1772P 英文标题：A Study Evaluating the Safety and Efficacy of Pyrotinib Dose Escalation Plus Loperamide Prophylaxis in First-Line Treatment of Advanced HER2-Positive Breast Cancer 中文标题：一项评估吡咯替尼剂量递增联合洛哌丁胺预防HER2阳性晚期乳腺癌一线治疗中安全性与有效性的研究讲者：晁腾飞（华中科技大学同济医学院附属同济医院）摘要号：1773P 英文标题：Neoadjuvant Oral Paclitaxel Plus Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab in Stage II-III HER2+ Breast Cancer: First-Stage Results from a Simon's Two-Stage Study 中文标题：口服紫杉醇联合皮下注射固定剂量帕妥珠单抗/曲妥珠单抗新辅助治疗II-III期HER2+乳腺癌：Simon两阶段设计第一阶段结果讲者：Yudong Li (Guangzhou, China) 摘要号：1775P 英文标题：Dalpiciclib plus Pyrotinib-Based Chemotherapy-Free Regimens as first line treatment in Trastuzumab-Sensitive, HER2-Positive Metastatic Breast Cancer (DAP-HER-02): A Dual-Cohort, Phase II Study 中文标题：达尔西利联合吡咯替尼无化疗方案一线治疗曲妥珠单抗敏感的HER2阳性转移性乳腺癌（DAP-HER-02）：一项双队列II期研究讲者：牛李敏（郑州大学第一附属医院）摘要号：1776P 英文标题：IBI354 plus pertuzumab as first-line (1L) treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer: Results from a phase 2 study 中文标题：IBI354联合帕妥珠单抗一线治疗HER2阳性不可切除局部晚期或转移性乳腺癌：一项II期研究结果讲者：曾晓华（重庆大学附属肿瘤医院）摘要号：1778P 英文标题：Updated results of SHR-A1811 plus pertuzumab in human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic breast cancer: a phase 1b/2 study 中文标题：SHR-A1811联合帕妥珠单抗治疗HER2阳性不可切除/转移性乳腺癌的更新结果：一项Ib/II期研究讲者：黄香（南京医科大学第一附属医院）摘要号：1779P 英文标题：Prognostic Impact of PIK3CA Mutations in HER2-Positive Advanced Breast Cancer: A Real-World Multicenter Study 中文标题：PIK3CA突变对HER2阳性晚期乳腺癌的预后影响：一项真实世界多中心研究讲者：王瓯晨（温州医科大学附属第一医院）摘要号：1781P 英文标题：Real-World Comparative Study of Pertuzumab- vs Pyrotinib-Based First-Line Regimens in HER2-Positive Advanced Breast Cancer: A Xinjiang Multicenter Study 中文标题：帕妥珠单抗对比吡咯替尼一线治疗HER2阳性晚期乳腺癌的真实世界比较：一项新疆多中心研究讲者：赵兵（新疆医科大学附属肿瘤医院）摘要号：1802eP 英文标题：Neoadjuvant Chemotherapy plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer: A Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST05) 中文标题：新辅助化疗联合吡咯替尼和曲妥珠单抗治疗HER2阳性乳腺癌：一项前瞻性、单臂、多中心研究（NEOTORCH-BREAST05）讲者：Zhijun Dai (Hangzhou, China) 摘要号：1803eP 英文标题：Multicenter, phase II study of eribulin, carboplatin, trastuzumab and pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer 中文标题：艾立布林、卡铂、曲妥珠单抗和帕妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌的多中心II期研究讲者：Di Lu (Chengdu, China) 摘要号：1810eP 英文标题：Inetetamab Combined with Pyrotinib for HER2-Positive Advanced Breast Cancer: A Multicenter Real-World Retrospective Study 中文标题：伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌：一项多中心真实世界回顾性研究讲者：Zenggui Wu (Taizhou, China) 摘要号：1812eP 英文标题：Enhanced protein lactylation accompanies acquired resistance to trastuzumab deruxtecan in HER2-positive breast cancer 中文标题：增强的蛋白乳酰化伴随HER2阳性乳腺癌对德曲妥珠单抗的获得性耐药讲者：Nan Jin (Nanjing, China) 摘要号：1814eP 英文标题：Antibody-programmable MOFs reshape multi-dimensional intervention strategies for programmed cell death in HER2+ breast cancer 中文标题：抗体可编程金属有机框架重塑HER2+乳腺癌程序性细胞死亡的多维干预策略讲者：王宇（首都医科大学附属北京同仁医院）摘要号：1818eP 英文标题：Characterization of Antibody Drug Conjugate-Associated Interstitial Lung Disease in Breast Cancer: A Systematic Review and Meta-Analysis 中文标题：乳腺癌抗体偶联药物相关间质性肺病的特征：系统综述与荟萃分析讲者：Yinuo Dong (Beijing, China) 摘要号：1823eP 英文标题：Ranking of First-Line Treatments for Advanced HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis 中文标题：HER2阳性晚期乳腺癌一线治疗的排序：贝叶斯网络荟萃分析讲者：Yuxin Sun (Beijing, China) 摘要号：1828eP 英文标题：Breast Ultrasound for Early Prediction of Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Real-World Analysis 中文标题：乳腺超声用于HER2阳性乳腺癌新辅助治疗疗效早期预测的真实世界分析讲者：Yuhang Xiao (Nanjing, China) 摘要号：1838eP 英文标题：FAP Expression Heterogeneity Drives Efficacy Variation of Targeted Radioligand Therapy and Patient Selection in HER2-Positive Breast Cancer 中文标题：FAP表达异质性驱动HER2阳性乳腺癌靶向放射性配体治疗的疗效差异与患者筛选讲者：Ting Wu (Luzhou, China) 摘要号：1841eTiP 英文标题：Al18F-HER2-BCH PET/CT guided precision neoadjuvant therapy for HER2-positive early breast cancer: FHERNAT trial 中文标题：Al18F-HER2-BCH PET/CT引导的HER2阳性早期乳腺癌精准新辅助治疗：FHERNAT试验讲者：梁旭（北京大学肿瘤医院） HR+ breast cancer（激素受体阳性乳腺癌）摘要号：1847P 英文标题：SHR-A2102, a Nectin-4-directed antibody drug conjugate (ADC), in pretreated HR+/HER2- advanced breast cancer: results from a phase 1 study 中文标题：SHR-A2102（靶向Nectin-4的ADC）用于经治HR+/HER2−晚期乳腺癌：一项I期研究结果讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1848P 英文标题：First-in-human study of JYP0035, a highly selective PI3Kα inhibitor, as monotherapy in patients with advanced solid tumors 中文标题：高选择性PI3Kα抑制剂JYP0035单药治疗晚期实体瘤的首次人体研究讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1849P 英文标题：A Phase 1b/2 Study of JS105 in Combination with Dalpiciclib and Fulvestrant in Patients with Advanced Breast Cancer 中文标题：JS105联合达尔西利和氟维司群治疗晚期乳腺癌的Ib/II期研究讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1852P 英文标题：Evaluation of the safety and efficacy of SH3765 in combination with fulvestrant in HR+/HER2− advanced breast cancer: a phase Ib study 中文标题：SH3765联合氟维司群治疗HR+/HER2−晚期乳腺癌的安全性与疗效评估：一项Ib期研究讲者：潘跃银（中国科学技术大学附属第一医院）摘要号：1858P 英文标题：BL0175 Injection for Locally Advanced/Metastatic HR+/HER2− Breast Cancer: Preliminary Results from Dose Escalation Stage of a Phase 1 Study 中文标题：BL0175注射液治疗局部晚期/转移性HR+/HER2−乳腺癌：I期剂量递增阶段初步结果讲者：王楠娅（吉林大学第一医院）摘要号：1859P 英文标题：First-line fovinaciclib for advanced breast cancer: updated analysis of a randomized, double-blind phase 3 study 中文标题：伏维西利一线治疗晚期乳腺癌：随机双盲III期研究更新分析讲者：袁芃（中国医学科学院肿瘤医院）摘要号：1869P 英文标题：Lysine acetyltransferase 6A (KAT6A) for predicting tamoxifen resistance in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer 中文标题：赖氨酸乙酰转移酶6A预测HR+/HER2−早期乳腺癌他莫昔芬耐药讲者：Tan Yujing (Beijing, China) 摘要号：1881P 英文标题：Clinical outcomes of YL202/BNT326 (HER3 ADC) in advanced/metastatic HR+/HER2-null/low breast cancer in chemotherapy-naïve and exposed patients 中文标题：YL202/BNT326（HER3 ADC）在初治和经治晚期/转移性HR+/HER2零表达/低表达乳腺癌中的临床结局讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1886TiP 英文标题：A phase I/II study of GenSci145 as monotherapy or combination therapy in PIK3CA-mutated advanced solid tumors 中文标题：GenSci145单药或联合治疗PIK3CA突变晚期实体瘤的I/II期研究讲者：徐兵河（中国医学科学院肿瘤医院）摘要号：1890eP 英文标题：Integrated Molecular Profiling of Paired Tumor Tissue and Circulating Tumor DNA in Chinese Patients with HR+/HER2- Advanced Breast Cancer Prior to First-Line Systemic Therapy 中文标题：中国HR+/HER2−晚期乳腺癌患者一线全身治疗前配对肿瘤组织与循环肿瘤DNA的整合分子分型讲者：岳健（中国医学科学院肿瘤医院）摘要号：1892eP 英文标题：An Open-label, Single-arm Study of Dalpiciclib in Combination with Aromatase Inhibitor and Capecitabine as Neoadjuvant Therapy for high-risk HR+/HER2- Early Breast Cancer 中文标题：达尔西利联合芳香化酶抑制剂和卡培他滨新辅助治疗高危HR+/HER2−早期乳腺癌：一项开放标签、单臂研究讲者：韩忠华（福建医科大学附属协和医院）摘要号：1893eP 英文标题：Dalpiciclib combined with endocrine therapy and capecitabine in high-risk HR+/HER2- advanced breast cancer: a multicenter phase II study 中文标题：达尔西利联合内分泌治疗和卡培他滨治疗高危HR+/HER2−晚期乳腺癌：一项多中心II期研究讲者：张捷（福建医科大学附属协和医院）摘要号：1895eP 英文标题：Early Toxicity-Driven Dose Modification Preserves Efficacy of Adjuvant Abemaciclib in High-Risk HR+/HER2− Early Breast Cancer: A Real-World Study in Chinese Patients 中文标题：早期毒性驱动的剂量调整不影响高危HR+/HER2−早期乳腺癌辅助阿贝西利疗效：一项中国患者真实世界研究讲者：Jing Huang (Xi'an, China) 摘要号：1896eP 英文标题：Fruquintinib plus eribulin in patients with metastatic HR+, HER2- breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study 中文标题：呋喹替尼联合艾立布林治疗内分泌治疗联合CDK4/6抑制剂进展后的转移性HR+/HER2−乳腺癌：II期研究更新结果讲者：袁渊（南京医科大学第一附属医院）摘要号：1898eP 英文标题：Real-World Outcomes of First-Line CDK4/6 Inhibitors Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Large National Cohort Study in China 中文标题：CDK4/6抑制剂联合内分泌治疗一线治疗HR+/HER2−晚期乳腺癌的真实世界结局：中国大型全国性队列研究讲者：罗扬（中国医学科学院肿瘤医院）摘要号：1903eP 英文标题：Patient-reported outcomes after switching from goserelin implant to goserelin microsphere in breast cancer: preliminary results of a prospective study 中文标题：乳腺癌患者从戈舍瑞林植入剂转换为戈舍瑞林微球后的患者报告结局：一项前瞻性研究初步结果讲者：张蓝心（大连医科大学附属第二医院）摘要号：1904eP 英文标题：CPS-EG Combined With Postoperative Ki-67 Outperforms ypTNM for Prognostication in HR+/HER2- Breast Cancer After Neoadjuvant Therapy: An 801-Patient Single-Center Retrospective Cohort Study 中文标题：CPS-EG联合术后Ki-67对HR+/HER2−乳腺癌新辅助治疗后预后的预测价值优于ypTNM：一项801例患者单中心回顾性队列研究讲者：Tian Yi Zhou (Guangzhou, China) 摘要号：1907eP 英文标题：Real-World Effectiveness and Safety of the Novel Agent Inavolisib in Heavily Pretreated, PIK3CA-mut Advanced Breast Cancer: A Multicenter Study of Patients with More Advanced and Complex Disease 中文标题：伊那利塞在重度经治PIK3CA突变晚期乳腺癌中的真实世界疗效与安全性：一项针对病情更晚期复杂疾病患者的多中心研究讲者：梁旭（北京大学肿瘤医院）摘要号：1911eP 英文标题：Optimal sequencing of systemic therapies for HR+/HER2− advanced breast cancer stratified by visceral and liver metastases: a systematic review and network meta-analysis 中文标题：按内脏和肝转移分层HR+/HER2−晚期乳腺癌全身治疗的最佳序贯策略：系统综述与网络荟萃分析讲者：Hong Cheng (Beijing, China) 摘要号：1918eP 英文标题：ABC-RWS-01 interim analysis of elacestrant in Chinese ESR1-mutated ER+/HER2- advanced breast cancer 中文标题：Elacestrant治疗中国ESR1突变ER+/HER2−晚期乳腺癌的ABC-RWS-01研究期中分析讲者：Wenbo Shi (Qionghai, China) 摘要号：1923eP 英文标题：Real-World Effectiveness and Safety of Maintenance Endocrine Therapy With or Without CDK4/6 Inhibitors Following Chemotherapy in HR-Positive/HER2-Negative Advanced Breast Cancer 中文标题：HR+/HER2-晚期乳腺癌化疗后维持内分泌治疗联合或不联合CDK4/6抑制剂的真实世界疗效与安全性讲者：李慧慧（山东省肿瘤医院）摘要号：1929eP 英文标题：Characterization of PIK3CA variants and real-world clinical evolution of first-line CDK4/6 inhibitors: Insights from a Chinese HR+/HER2- advanced breast cancer cohort 中文标题：PIK3CA变异特征与一线CDK4/6抑制剂治疗的真实世界临床演变：来自中国HR+/HER2−晚期乳腺癌队列的见解讲者：石晶（中国医科大学附属第一医院）摘要号：1936eP 英文标题：Safety profile of exemestane vs. anastrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports 中文标题：依西美坦对比阿那曲唑的真实世界安全性：FAERS数据库不相称性分析与病例报告系统综述讲者：Chunsu Liang (Beijing, China) 摘要号：1943eTiP 英文标题：SoGreat: A phase Ib modular study of sacituzumab govitecan plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer after progression on CDK4/6 inhibitors 中文标题：SoGreat：戈沙妥珠单抗联合内分泌治疗用于CDK4/6抑制剂进展后HR+/HER2-转移性乳腺癌的Ib期模块化研究讲者：Zhonghui Zheng (Shanghai, China) 摘要号：1944eTiP 英文标题：The NASA (Neoadjuvant Ribociclib plus Aromatase Inhibitor) Trial: A randomized comparison versus chemotherapy in HR+/HER2- EBC 中文标题：NASA试验（新辅助哌柏西利联合芳香化酶抑制剂）：HR+/HER2−早期乳腺癌中对比化疗的随机对照研究讲者：蔡子杰（中山大学孙逸仙纪念医院） Supportive care（支持治疗）摘要号：3950P 英文标题：Musculoskeletal pain, neutrophil recovery kinetics, and exploratory immune-profiling with telpegfilgrastim versus other long-acting G-CSFs in breast cancer: TELEGRAM 中文标题：乳腺癌中拓培非格司亭对比其他长效G-CSF的肌肉骨骼疼痛、中性粒细胞恢复动力学及探索性免疫分型：TELEGRAM研究讲者：李薇（南京医科大学第一附属医院）摘要号：4028eP 英文标题：Efficacy and safety of telpegfilgrastim in breast cancer patients undergoing (neo)adjuvant chemotherapy for prophylaxis of chemotherapy-induced neutropenia: A multicenter, prospective, observational study 中文标题：拓培非格司亭在乳腺癌（新）辅助化疗患者预防化疗所致中性粒细胞减少的疗效与安全性：一项多中心、前瞻性、观察性研究讲者：张少华（解放军总医院）摘要号：4057eP 英文标题：Prospective Cohort Study on the Prophylaxis of Catheter-related Thrombosis in Breast Cancer Patients 中文标题：乳腺癌患者导管相关血栓预防的前瞻性队列研究讲者：Shiyu Li (Beijing, China) 摘要号：4071eP 英文标题：Auricular point stimulation plus dexamethasone for nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy (ADDC) 中文标题：耳穴刺激联合地塞米松用于乳腺癌辅助化疗多西他赛联合环磷酰胺所致恶心呕吐（ADDC研究）讲者：Juan Wang (Hangzhou, China) 摘要号：4138eP 英文标题：Physiological and Functional Responses to Ultrasound-Guided Dextrose Hydrodissection in Breast Cancer Survivors With Persistent Chest Wall and Axillary Tightness 中文标题：超声引导下葡萄糖水分离术对持续性胸壁和腋窝紧绷的乳腺癌幸存者的生理与功能反应讲者：Yuchun Lee（中国台湾台中市） Triple negative breast cancer（三阴性乳腺癌）摘要号：4651P 英文标题：Competing risk nomogram for cancer-specific mortality and risk-stratified treatment associations in women with T2N0M0 triple-negative breast cancer: a SEER study (2010-2016) 中文标题：T2N0M0三阴性乳腺癌患者癌症特异性死亡竞争风险列线图及风险分层治疗关联：一项SEER研究（2010-2016）讲者：Sirui Zhu (Beijing, China) 摘要号：4652P 英文标题：225Ac-PSMA-targeted alpha therapy (TRC003) in metastatic TNBC: A prospective, multicenter, single-arm safety/efficacy trial 中文标题：225Ac-PSMA靶向α核素治疗（TRC003）在转移性TNBC中的应用：一项前瞻性、多中心、单臂安全性与疗效试验讲者：孙晓蓉（山东第一医科大学附属肿瘤医院）摘要号：4653P 英文标题：A phase 2, multicenter, open-label study to evaluate the efficacy and safety of ATRA plus toripalimab and chemotherapy in patients with previously treated locally advanced or metastatic triple-negative breast cancer 中文标题：ATRA联合特瑞普利单抗和化疗治疗经治局部晚期或转移性三阴性乳腺癌的II期多中心开放标签研究讲者：陶中华（复旦大学附属肿瘤医院）摘要号：4655P 英文标题：Efficacy and Safety of First-Line Treatment for Advanced Triple-Negative Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials 中文标题：晚期三阴性乳腺癌一线治疗的疗效与安全性：随机对照试验网络荟萃分析讲者：Junxiao Wang (Fuzhou, China) 摘要号：4657P 英文标题：Subtyping-guided addition of bevacizumab to treatment of physician's choice for previously untreated, advanced, basal-like immune-suppressed triple-negative breast cancer (OASIS/BCTOP-T-M01): a randomised, multicentre, phase 3 trial 中文标题：分型指导的贝伐珠单抗联合医生选择方案治疗初治晚期基底样免疫抑制型三阴性乳腺癌（OASIS/BCTOP-T-M01）：一项随机、多中心III期试验讲者：马林晓曦（复旦大学附属肿瘤医院）摘要号：4678P 英文标题：The Efficacy and Safety of Utidelone Plus Tislelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) 中文标题：优替德隆联合替雷利珠单抗和贝伐珠单抗治疗晚期或转移性三阴性乳腺癌（UTILIZABLE研究）讲者：Qingxu Liu (Wuhan, China) 摘要号：4680eP 英文标题：Identification of angiogenesis-related diagnostic and prognostic gene signatures for triple-negative breast cancer via machine learning and single-cell analysis 中文标题：基于机器学习和单细胞分析鉴定三阴性乳腺癌血管生成相关诊断和预后基因特征讲者：Hanbo Wang (Tianjin, China) 摘要号：4682eP 英文标题：Isojacareubin induces apoptosis of chemoresistant-triple negative breast cancer by epigenetic repression of PIK3CA via deacetylation of Histone 3 lysine 56 中文标题：异山竹素通过组蛋白H3K56去乙酰化表观遗传抑制PIK3CA诱导化疗耐药三阴性乳腺癌凋亡讲者：Dar-Ren Chen（中国台湾彰化市）摘要号：4686eP 英文标题：Single-cell transcriptomics reveals drivers of tumor microenvironment reprogramming and immunotherapy resistance in triple-negative breast cancer 中文标题：单细胞转录组学揭示三阴性乳腺癌肿瘤微环境重编程和免疫治疗耐药的驱动因素讲者：Shuangqi Qian (Tianjin, China) 摘要号：4690eP 英文标题：Association of PCSK9 Inhibitor Use With Breast Cancer Survival and Recurrence: A Target Trial Emulation 中文标题：PCSK9抑制剂使用与乳腺癌生存和复发的关联：目标试验模拟讲者：Salida Ali（中国香港）摘要号：4693eP 英文标题：PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study 中文标题：PD-1抑制剂信迪利单抗联合表柔比星、环磷酰胺和白蛋白紫杉醇新辅助治疗三阴性乳腺癌：一项单臂II期研究讲者：Duanyang Zhai (Guangzhou, China) 摘要号：4695eP 英文标题：Carboplatin plus taxanes combined with or without PD-1 inhibitors as neoadjuvant therapy in triple-negative breast cancer: A Propensity-Matched Cohort Study 中文标题：卡铂联合紫杉类联合或不联合PD-1抑制剂新辅助治疗三阴性乳腺癌：一项倾向性匹配队列研究讲者：Hongwei Lyu (Beijing, China) 摘要号：4700eP 英文标题：Radiological Complete Response as a Predictor of Neoadjuvant Therapy Efficacy in Early Triple-Negative Breast Cancer: A Multicenter Real-World Study 中文标题：影像学完全缓解作为早期三阴性乳腺癌新辅助治疗疗效的预测因素：一项多中心真实世界研究讲者：Wenyu Yang (Beijing, China) 摘要号：4702eP 英文标题：A Tumor Cell Membrane-Based FTY720 Nanoplatform Synergizes with [177Lu]Lu Radionuclide Therapy for Triple-Negative Breast Cancer 中文标题：基于肿瘤细胞膜的FTY720纳米平台协同[177Lu]Lu放射性核素治疗三阴性乳腺癌讲者：Yuyue Hou (Wuhan, China) 摘要号：4724eP 英文标题：Predictive value of tertiary lymphoid structures for immunotherapy efficacy in triple-negative breast cancer 讲者：三级淋巴结构对三阴性乳腺癌免疫治疗疗效的预测价值讲者：刘月平（河北医科大学第四医院）摘要号：4732eP 英文标题：Landscape of Peripheral Immune Response Induced by Multimodal Thermal Therapy Combined with Chemoimmunotherapy in Patients with Early-stage Triple-negative Breast Cancer 中文标题：多模式热疗联合化学免疫治疗诱导早期三阴性乳腺癌患者外周免疫应答的全景分析讲者：Fei Lin Qu (Shanghai, China) AI for clinical workflows and decision-making（人工智能辅助临床工作流程与决策）摘要号：208P 英文标题：Multimodal Unified Survival Ensemble (MUSE) Predicts Immunotherapy Survival Benefit in Triple-negative Breast Cancer (TNBC): Analysis from the TORCHLIGHT Study 中文标题：多模态统一生存集成模型预测三阴性乳腺癌免疫治疗生存获益：TORCHLIGHT研究分析讲者：江泽飞（解放军总医院） AI for diagnostics and profiling (pathology, radiology, molecular biology)（人工智能辅助诊断与分子分型）摘要号：300P 英文标题：BRIGHT: a breast pathology foundation model for biomarker prediction and treatment stratification in breast cancer 中文标题：BRIGHT：用于乳腺癌生物标志物预测与治疗分层的基础病理模型讲者：刘芳芳（天津医科大学肿瘤医院）摘要号：314P 英文标题：Study on the association between HER2 expression in breast cancer and spatial heterogeneity of microvascular density 中文标题：乳腺癌HER2表达与微血管密度空间异质性的关联研究讲者：Jingyue Li (Shenyang, China) 摘要号：331P 英文标题：An Interpretable Whole-slide Image Framework for Automated Trop-2 H-score Assessment in Breast Cancer 中文标题：可解释的全玻片图像框架用于乳腺癌Trop-2 H-score自动评估讲者：刘月平（河北医科大学第四医院）摘要号：355P 英文标题：A Multimodal Model Integrating Therapeutic Response Patterns and AI-Powered Pathology for Survival Prediction in Breast Cancer After Neoadjuvant Therapy 中文标题：整合治疗反应模式与人工智能病理的多模态模型用于乳腺癌新辅助治疗后生存预测讲者：刘月平（河北医科大学第四医院） Developmental therapeutics（药物研发）摘要号：1119eP 英文标题：Nitazoxanide Induces Ferroptosis in Triple-Negative Breast Cancer by Dual Reprogramming of Iron Metabolism and the β-catenin/GPX4 Axis 中文标题：硝唑尼特通过双重重编程铁代谢和β-catenin/GPX4轴诱导三阴性乳腺癌铁死亡讲者：Tao He (Luzhou, China) Psycho-oncology（心理肿瘤学）摘要号：3495eP 英文标题：Machine Learning Models for Depression Risk Prediction in Breast Cancer Patients: A Cross-Sectional Study Based on the NHANES Database 中文标题：基于NHANES数据库的机器学习模型预测乳腺癌患者抑郁风险：一项横断面研究讲者：Junxiao Wang (Fuzhou, China) Translational research and biomarkers（转化研究与生物标志物）摘要号：4587eP 英文标题：Temperature-Responsive PDDNFs@QDs Integrating Simplified Isolation for Efficient Exosome Analysis Enables Breast Cancer Diagnosis and Subtyping 中文标题：温敏型PDDNFs@QDs整合简化分离实现高效外泌体分析用于乳腺癌诊断与分型讲者：Xiangyue Meng (Chengdu, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床2期临床结果

20 小时之前

·ioncology

ESMO 2026丨瞭望前瞻，50余项中国妇科肿瘤研究亮相ESMO，一文速览

编者按 2026年欧洲肿瘤内科学会（ESMO）年会于10月23日至27日在西班牙马德里盛大举办。作为全球肿瘤领域极具影响力的顶级学术盛会，年会汇聚了全球顶尖肿瘤临床专家、科研学者及医药行业从业者，集中展示肿瘤领域前沿基础研究与临床转化成果，引领全球肿瘤诊疗技术发展方向。本次大会妇科肿瘤赛道硕果颇丰，多位中国专家携重磅研究成果亮相，涵盖宫颈癌、卵巢癌、子宫内膜癌等常见妇科恶性肿瘤的靶向治疗、免疫治疗、联合放化疗、真实世界研究及多组学机制探索等多个热门方向，充分展现了中国妇科肿瘤领域的科研实力与临床创新水平。本文系统整理本次ESMO年会收录的中国专家口头报告、壁报研究成果，以期为行业学术交流与临床研究参考提供翔实资料。 ✦ 快速口头报告摘要号：1240RO 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial中文标题：艾帕洛利托沃瑞利单抗（QL1706）联合化疗±贝伐珠单抗一线治疗持续性、复发性或转移性宫颈癌：一项双盲、随机、安慰剂对照Ⅲ期临床试验结果讲者：刘继红教授中山大学肿瘤防治中心摘要号：1243RO 英文标题：JSKN033, a first-in-class subcutaneous (SC)-injected fixed-dose combination (FDC) of biparatopic anti-HER2 ADC and PD-L1 inhibitor, in pre-treated cervical cancer中文标题：全球首创皮下注射双表位抗HER2 ADC联合PD-L1抑制剂固定复方制剂JSKN033用于经治宫颈癌的临床研究讲者：吴小华教授复旦大学附属肿瘤医院妇瘤科摘要号：1244RO 英文标题：SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study中文标题：新型Nectin-4靶向抗体药物偶联物SHR-A2102治疗复发/转移性宫颈癌Ⅱ期临床研究结果讲者：刘继红教授中山大学肿瘤防治中心 ✦ 壁报+电子壁报摘要号：1348eP 英文标题：Association of location of BRCA1/BRCA2 mutations and benefit from PARP inhibitor maintenance in ovarian cancer: a systemic review中文标题：卵巢癌BRCA1/BRCA2突变位点与PARP抑制剂维持治疗获益相关性的系统综述讲者：Ming Wang (Beijing, China) 摘要号：1359eP 英文标题：Role of BTLA in Ovarian Cancer and Its Clinical Prognostic Significance Based on Multi-Omics Analysis.中文标题：基于多组学分析BTLA在卵巢癌中的作用及其临床预后价值讲者：Yiliminuer Abulajiang (Beijing, China) 摘要号：1362eP 英文标题：Multi-omics provide insights into the effect of neoadjuvant chemotherapy on the tumor microenvironment in cervical cancer中文标题：多组学解析新辅助化疗对宫颈癌肿瘤微环境的调控作用讲者：Silu Meng (Wuhan, China) 摘要号：1365eP 英文标题：Updated Efficacy and Safety Data of First-Line Anlotinib + Carboplatin/Paclitaxel Induction Followed by Anlotinib Maintenance in Advanced Ovarian Cancer: Phase II Multicenter Trial (ALTER-GO-010)中文标题：安罗替尼联合卡铂/紫杉醇诱导后安罗替尼维持一线治疗晚期卵巢癌多中心Ⅱ期研究（ALTER-GO-010）更新疗效与安全性数据讲者：Wenjun Cheng (Nanjing, China) 摘要号：1367eP 英文标题：CD8+/FOXP3+ Tumor-Infiltrating Lymphocytes and Systemic Immune-Inflammation Index revealed as a Predictor to Neoadjuvant Cadonilimab Plus Chemotherapy in Advanced Ovarian Cancer from the Phase II CANECT Trial中文标题：Ⅱ期CANECT研究证实CD8+/FOXP3+肿瘤浸润淋巴细胞与全身免疫炎症指数可预测卡度尼利单抗联合化疗新辅助治疗晚期卵巢癌疗效讲者：Jie Tang (Changsha, China) 摘要号：1368eP 英文标题：Clinical Practice Patterns of HER2 Testing and Treatment in Endometrial Cancer in China: A Cross-Sectional Survey中文标题：中国子宫内膜癌HER2检测与治疗临床实践现状横断面调查讲者：Jihong Liu (Guangzhou, China) 摘要号：1371eP 英文标题：Hyperthermic Intraperitoneal Treatment to Enhance the Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Ovarian Cancer: Stage 1 Results of a Phase II Trial (HIPET-IO) (NCT07068178)中文标题：腹腔温热治疗提升晚期卵巢癌免疫检查点抑制剂疗效：Ⅱ期HIPET-IO研究（NCT07068178）I阶段结果讲者：Hui Li (Guangzhou, China) 摘要号：1379eP 英文标题：Safety, Immunogenicity, and Efficacy of RG002, an mRNA-LNP-Based Therapeutic Targeting HPV 16/18 E2/E6/E7, in Patients with CIN2/3: Results from a Phase I and Expanded Clinical Study中文标题：靶向HPV16/18 E2/E6/E7的 mRNA-LNP 治疗疫苗RG002用于CIN2/3患者的安全性、免疫原性及疗效I期及扩展临床研究结果讲者：Shan Cen (Beijing, China) 摘要号：1382eP 英文标题：Study on the Comparison between Fangzhi Decoction and Kangfuxin in Preventing Gastrointestinal Toxicity Induced by Concurrent Chemoradiotherapy for Cervical Cancer中文标题：防芷汤与康复新液预防宫颈癌同步放化疗所致胃肠道毒性对比研究讲者：Shengfa Su (Guiyang, China) 摘要号：1386eP 英文标题：Exploratory study of TP53 mutations in circulating tumor DNA as prognostic and longitudinal monitoring biomarkers for relapsed ovarian carcinoma patients中文标题：循环肿瘤DNA TP53突变作为复发性卵巢癌预后及动态监测生物标志物探索研究讲者：Zheng Feng (Shanghai, China) 摘要号：1388eP 英文标题：Rapid Histopathological Regression of CIN2 with APL-1702 Photodynamic Therapy: Preliminary Findings from a Multicenter Study中文标题：APL-1702光动力治疗实现CIN2快速组织病理学缓解：一项多中心研究初步结果讲者：Yu Zhang (Changsha, China) 摘要号：1394eP 英文标题：Intimate Partner Violence-Related Stress Accelerates Cervical Cancer Development via a Brain–Cholinergic Nerve–Tumor Axis中文标题：亲密伴侣暴力相关应激通过脑-胆碱能神经-肿瘤轴促进宫颈癌进展讲者：Jingrui Jiang (Wuhan, China) 摘要号：1395eP 英文标题：Association of Silva Pattern C with Lymph Node Metastasis Count and Prognosis in Cervical Adenocarcinoma After Radical Hysterectomy : Construction of a Nomogram Prediction Model.中文标题：宫颈腺癌根治术后Silva C型与淋巴结转移数目及预后相关性：列线图预测模型构建讲者：Jiehui Li (Guiyang, China) 摘要号：1396eP 英文标题：Clinical landscape of oncolytic virotherapy in gynecologic malignancies中文标题：溶瘤病毒疗法在妇科恶性肿瘤中的临床应用全景讲者：Kaiyu Fu (Chengdu, China) 摘要号：1403eP 英文标题：RBP4 orchestrates metabolic reprogramming of ovarian cancer and the omentum microenvironment for cancer dissemination中文标题：RBP4调控卵巢癌及大网膜微环境代谢重编程促进肿瘤播散讲者：Weiao Qu (Tianjin, China) 摘要号：1405eP 英文标题：Single-cell RNA sequencing reveals the important role of intercommunication between epithelial cells and cancer-associated fibroblasts in the peritoneal metastasis of high-grade serous ovarian cancer中文标题：单细胞RNA测序揭示上皮细胞与癌相关成纤维细胞互作在高级别浆液性卵巢癌腹膜转移中的关键作用讲者：Xiaoting Zhao (Beijing, China) 摘要号：1406eP 英文标题：Therapy-selected primitive hematopoietic clones in PARP inhibitor–associated t-MN: longitudinal single-cell insights from ovarian cancer中文标题：PARP抑制剂相关治疗相关髓系肿瘤中经药物筛选的原始造血克隆：卵巢癌患者纵向单细胞研究讲者：Yuanqiong Duan (Chengdu, China) 摘要号：1407eP 英文标题：HPV18 is a poor prognostic factor in patients with small cell neuroendocrine cervical cancer.中文标题：HPV18是宫颈小细胞神经内分泌癌不良预后因素讲者：Chyong-Huey Lai (Taoyuan City, Taiwan) 摘要号：1412eP 英文标题：Anxiety-driven sympathetic nerve–CAF–NGF axis promotes ovarian cancer progression and immune evasion中文标题：焦虑介导交感神经-癌相关成纤维细胞-NGF轴促进卵巢癌进展与免疫逃逸讲者：Yueming Zhang (Suzhou, China) 摘要号：1416eP 英文标题：Clinical Characteristics Analysis of a Single-Cell and Spatial Transcriptomics Cohort Treated with Zimberelimab Combined with Chemoradiotherapy for Intermediate- and Advanced-Stage Cervical Cancer中文标题：基于单细胞及空间转录组队列分析Zimberelimab联合放化疗治疗中晚期宫颈癌的临床特征讲者：Yunyan Zhang (Harbin, China) 摘要号：1420eP 英文标题：Epidemiology and Treatment Options for Cervical Cancer Patients Aged ≤25 Years based on SEER database and Real world research中文标题：基于SEER数据库与真实世界研究的25岁及以下宫颈癌患者流行病学特征及治疗方案分析讲者：Chen Ji (Beijing, China) 摘要号：1425eP 英文标题：Real-world outcomes of FRα targeting treatment with MIRV in Chinese PROC patients中文标题：MIRV靶向叶酸受体α治疗中国铂耐药卵巢癌患者真实世界疗效讲者：Jing Li (Shanghai, China) 摘要号：1426eP 英文标题：Correlation Between Recurrence Patterns and Clinical Risk Factors Following Prophylactic Irradiation of the the Inguinal Lymphatic Drainage Area in Stage IIIA Cervical Cancer中文标题：IIIA期宫颈癌腹股沟淋巴引流区预防性放疗后复发模式与临床危险因素相关性讲者：Fenghu Li (Guiyang, China) 摘要号：1427eP 英文标题：Clinical Characteristics and Treatment Strategy Analysis of 21 Cervical Cancer Patients Undergoing Hysterectomy After Radical Radiotherapy中文标题：21例根治性放疗后接受子宫切除术宫颈癌患者临床特征与治疗策略分析讲者：Zhuoying Du (Beijing, China) 摘要号：1428eP 英文标题：Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 Bifunctional Antibody) Plus Chemotherapy Enables Radical Surgery in Locally Advanced Cervical Cancer中文标题：PD-1/CTLA-4双特异性抗体艾帕洛利托沃瑞利单抗新辅助化疗可实现局部晚期宫颈癌根治性手术讲者：Wei Sheng (Jinan, China) 摘要号：1430eP 英文标题：Reduced-Dose Dexamethasone (Dex) Plus Netupitant/Palonosetron (NEPA) for Prevention of Nausea and Vomiting in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy（CCRT）: An Interim Analysis中文标题：减量地塞米松联合奈妥匹坦/帕洛诺司琼预防宫颈癌同步放化疗恶心呕吐中期分析讲者：Re Yang (Guiyang, China) 摘要号：1440eP 英文标题：MEOX2 promotes the survival and dissemination of ovarian cancer cells via the activation of UPR under nutrient stress中文标题：营养应激下MEOX2通过激活未折叠蛋白反应促进卵巢癌细胞存活与播散讲者：Rui Zhou (Tianjin, China) 摘要号：1441eTiP 英文标题：Prospective Single-Arm Exploratory Study of Disitamab Vedotin Combination Regimen as Neoadjuvant Therapy for HER2-Expressing Ovarian Cancer中文标题：维迪西妥单抗联合方案用于HER2表达卵巢癌新辅助治疗前瞻性单臂探索研究讲者：Jing X. Tong (Shenyang, China) 摘要号：1253P 英文标题：Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) JSKN003 in Platinum-Resistant Ovarian Cancer (PROC): updated Overall Survival (OS) Analysis from Two Early-Phase Studies After Median Follow-Up (mFU) of 20.5 Months中文标题：双表位抗HER2 ADC药物JSKN003治疗铂耐药卵巢癌：两项早期研究中位随访20.5个月更新总生存数据讲者：Xiaohua Wu (Shanghai, China) 摘要号：1254P 英文标题：Disitamab Vedotin (RC48)-based Therapy in Heavily Prior Treated Patients with Recurrent Ovarian Cancer: A Real-World Multicenter Study中文标题：基于维迪西妥单抗（RC48）方案治疗多线经治复发性卵巢癌多中心真实世界研究讲者：Lei Yuan (Shanghai, China) 摘要号：1255P 英文标题：Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) in patients with platinum-resistant ovarian cancer (PROC): Efficacy and safety data from a Phase 2 dose optimization cohort中文标题：B7H3 ADC药物 Elfetabart drozuntecan（DB-1311/BNT324）治疗铂耐药卵巢癌Ⅱ期剂量优化队列疗效与安全性数据讲者：Jianqing Zhu (Hangzhou, China) 摘要号：1259P 英文标题：Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) in Post-Platinum Advanced Mismatch Repair Proficient (pMMR) Endometrial Cancer (EC): Results From a Phase 2 Study (2870-002/SKB264-II-06)中文标题：芦康沙妥珠单抗联合帕博利珠单抗治疗铂耐药晚期错配修复完整子宫内膜癌Ⅱ期研究结果（2870-002/SKB264-II-06）讲者：Xiaohua Wu (Shanghai, China) 摘要号：1260P 英文标题：Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC)中文标题：FLAMES研究更新无进展生存数据：塞那帕利一线维持治疗初诊晚期卵巢癌讲者：Xiaohua Wu (Shanghai, China) 摘要号：1265P 英文标题：3-year survival outcomes of image-guided radiotherapy combined with nimotuzumab for elderly patients with locally advanced cervical squamous cell carcinoma: a multi-center phase 2 trial中文标题：图像引导放疗联合尼妥珠单抗治疗老年局部晚期宫颈鳞癌3年生存结局多中心Ⅱ期研究讲者：Ang Qu (Beijing, China) 摘要号：1271P 英文标题：Efficacy and Safety of MSLN-Specific Autologous CAR-T Cell Therapy in Patients with Recurrent Ovarian Cancer: An Investigator-Initiated Single-Arm Clinical Trial中文标题：间皮素靶向自体CAR-T细胞治疗复发性卵巢癌疗效与安全性：一项研究者发起单臂临床试验讲者：Guohui Qin (Zhengzhou, China) 摘要号：1276P 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and definitive radiotherapy as first-line treatment for oligometastatic cervical cancer: a single-arm, phase II study中文标题：艾帕洛利托沃瑞利单抗（QL1706）化疗同步根治性放疗一线治疗寡转移宫颈癌单臂Ⅱ期研究讲者：Jing Liu (Jinan, China) 摘要号：1277P 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab induced concurrent chemoradiotherapy for high-risk locally advanced cervical cancer: A Prospective, Single-Arm Phase II Clinical Trial中文标题：艾帕洛利托沃瑞利单抗（QL1706）±贝伐珠单抗化疗诱导同步放化疗治疗高危局部晚期宫颈癌前瞻性单臂Ⅱ期临床研究讲者：Xiao'juan Lv (Hangzhou, China) 摘要号：1280P 英文标题：Long Term Follow-up Results from a Phase I/II Study of Nilvanstomig (ZG005), a Bispecific Antibody Targeting PD-1 and TIGIT, as Monotherapy in Patients with Advanced Cervical Cancer中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）单药治疗晚期宫颈癌I/Ⅱ期长期随访结果讲者：Shuxia Cheng (Zhengzhou, China) 摘要号：1282P 英文标题：Phase I/II Study of Nilvanstomig (ZG005) Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment for Advanced Cervical Cancer: Updated Results of Efficacy and Safety中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）联合化疗±贝伐珠单抗一线治疗晚期宫颈癌 I/Ⅱ期更新疗效与安全性数据讲者：Hanmei Lou (Hangzhou, China) 摘要号：1283P 英文标题：Phase II Study of Fruquintinib Plus Utidelone in Platinum-Resistant Recurrent Ovarian Cancer (FRUTD Trial)中文标题：呋喹替尼联合优替德隆治疗铂耐药复发性卵巢癌Ⅱ期FRUTD临床研究讲者：Zheng Feng (Shanghai, China) 摘要号：1289P 英文标题：Subtype-Specific Outcomes and Risk-Adapted Treatment Patterns in Endometrial Stromal Sarcoma: A 214-Patient Retrospective Cohort中文标题：子宫内膜间质肉瘤各亚型生存结局及风险分层治疗模式：214例患者回顾性队列研究讲者：Lingcong Yang (Fuzhou, China) 摘要号：1297P 英文标题：Preliminary outcomes of a phase II study of the highly potent PI3K/mTOR dual inhibitor WX390 monotherapy in patients with platinum-resistant ovarian clear cell carcinoma harboring PIK3CA mutations中文标题：高选择性PI3K/mTOR双靶点抑制剂WX390单药治疗伴PIK3CA突变铂耐药卵巢透明细胞癌Ⅱ期初步结果讲者：Jiajia Li (Shanghai, China) 摘要号：1301P 英文标题：A real-world study of patients with gastric-type adenocarcinoma of the cervix中文标题：宫颈胃型腺癌患者真实世界临床研究讲者：Mengting Che (Chengdu, China) 摘要号：1303P 英文标题：Efficacy of Iparomlimab and Tuvonralimab (QL1706) in Cervical Cancer: A Multicenter, Prospective, Real-World Study中文标题：艾帕洛利托沃瑞利单抗（QL1706）治疗宫颈癌多中心前瞻性真实世界疗效研究讲者：Yan Lu (Nantong, China) 摘要号：1315P 英文标题：Redefining risk in cervical cancer: a novel histology-site subtype framework uncovers high- Risk adenocarcinoma through risk reversal中文标题：宫颈癌风险分层再定义：全新组织 - 解剖分型体系通过风险反转识别高危腺癌亚型讲者：Xiaolian Peng (Dongguan, China) 摘要号：1326P 英文标题：Induction Weekly Chemoimmunotherapy with Enlonstobart as a Priming Approach to De-escalated Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer中文标题：恩朗苏拜单抗周疗化疗免疫诱导方案用于局部晚期宫颈癌降阶梯同步放化疗预处理讲者：Ai Huang (Wuhan, China) 摘要号：1327P 英文标题：Longitudinal Changes of Systemic Tumoe Immune Envoriment (STIE) in Cervical Cancer Patients Receiving Radiotherapy中文标题：接受放疗的宫颈癌患者全身肿瘤免疫微环境纵向动态变化规律讲者：Caining Zhao (Shenzhen, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

22 小时之前

·医脉通

双抗ADC新“食”代｜曹国春教授：全球首个双抗ADC伦康依隆妥单抗获批食管鳞癌适应证，PFS与OS双获益确立二线治疗新标准

导语 2026年7月16日，NMPA官网显示，百利天恒自主研发的全球首创（First-in-class）全新概念EGFR×HER3双抗ADC药物，iza-bren（商品名：宜泽康，通用名：伦康依隆妥单抗）获国家药品监督管理局（NMPA）批准用于治疗既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞状细胞癌的成人患者。图1 截图来自NMPA官网本次获批主要基于北京大学肿瘤医院沈琳教授团队牵头开展的PANKU-Esophagus01研究的阳性结果。与研究者选择的单药化疗相比，伦康依隆妥单抗PFS 4.17个月（HR=0.50），是化疗（1.97个月）的2倍多，6个月PFS率32.7%，同样为化疗（14.7%）的2倍多；中位OS 9.79个月（HR=0.64），死亡风险下降36%，12个月OS率34.8%，较化疗（22.5%）显著提升。客观缓解率（ORR）达35.3%，是化疗（13.1%）的近3倍1。伦康依隆妥单抗以扎实的临床数据和明确的生存获益，填补了食管鳞癌免疫耐药人群二线治疗空白，将重塑治疗格局，也代表食管鳞癌正式迈入双抗ADC治疗新时代。值此之际，医脉通特邀江苏省肿瘤医院曹国春教授，围绕双抗ADC的机制创新、临床数据解读及未来方向进行深度问答，以飨读者。填补空白伦康依隆妥单抗为ESCC二线治疗确立新标杆问题一：食管鳞癌是我国特有的高发瘤种，长期以来二线治疗缺乏高级别证据支持的标准方案。您认为伦康依隆妥单抗此次获批对这一领域的临床实践带来了哪些根本性的改变？从药物设计角度，双抗ADC相较于传统ADC有哪些技术优势？曹国春教授食管鳞癌的治疗在过去数年间经历了显著变化。一线治疗方面，免疫检查点抑制剂联合化疗已成为标准方案，多项大型III期研究证实其相比单纯化疗可显著延长患者OS2。然而，一线治疗失败后的二线选择，长期以来缺乏高级别循证医学证据支持。临床实践中，医生多依据个人经验选择多西他赛、紫杉醇或伊立替康等单药化疗，但这些方案的有效率不足10%，中位PFS仅2~3个月，中位OS约为6~7个月，临床获益极为有限，各大指南的推荐等级亦普遍偏低3-5。伦康依隆妥单抗的获批，为这一人群提供了首个具备大型III期随机对照试验循证依据的标准治疗选择。PANKU-Esophagus01研究以PFS和OS双主要终点均取得阳性结果，证实了在免疫联合化疗进展后，双抗ADC依然能够带来明确的生存获益。这不仅填补了二线治疗的循证空白，更使临床决策从经验性选择转向有高质量证据支撑的标准路径。伦康依隆妥单抗作为双抗ADC，其抗体部分可同时结合EGFR和HER3两个靶点，这种设计具有多重机制优势6。其一，双靶点的设计有助于提高对肿瘤细胞的选择性识别，降低对仅表达单个抗原的正常组织的非特异性结合。其二，双抗可促进抗体-抗原复合物的协同内化，使载荷更高效地进入肿瘤细胞内部。其三，同时阻断EGFR和HER3两条信号通路，可在一定程度上延缓或克服肿瘤的耐药机制。此外，伦康依隆妥单抗搭载的Ed-04载荷属于新型拓扑异构酶I抑制剂，药物抗体比达到8，显著高于第一代ADC常见的2~4；其连接子采用酸性稳定化改造设计，在血浆中不易裂解，有效减少了载荷提前释放带来的全身毒性7。上述技术特征共同支撑了其在临床研究中取得的高缓解率和明确生存获益。硬核数据 PFS翻倍、OS显著延长，伦康依隆妥单抗用证据定义标准问题二：PANKU-Esophagus01研究是支持此次获批的关键性证据。请您解读一下该研究的主要疗效数据和安全性表现，以及这些结果对临床实践的意义？曹国春教授 PANKU-Esophagus01是一项多中心、随机、开放标签的III期研究，共入组497例一线接受过PD-1/PD-L1抑制剂联合铂类化疗后出现疾病进展的复发或转移性食管鳞癌患者。患者按1:1随机分配至伦康依隆妥单抗组或研究者选择的单药化疗组（包括多西他赛、紫杉醇或伊立替康）。研究采用PFS和OS双主要终点设计，由独立评审委员会评估。结果显示，伦康依隆妥单抗组中位PFS为4.17个月，化疗组仅为1.97个月，疾病进展或死亡风险降低50%，6个月PFS率32.7%，为化疗（14.7%）的2倍多，这一结果在统计学和临床意义上均高度显著。中位OS方面，伦康依隆妥单抗组为9.79个月，化疗组为7.20个月，12个月OS率34.8%，较化疗（22.5%）显著提升，死亡风险降低36%。ORR方面，伦康依隆妥单抗组为35.3%，化疗组为13.1%，提升至近三倍1。这些数据的临床意义可以从两个层面来理解。其一，在传统化疗几乎无效的免疫耐药人群中，双抗ADC依然能够实现超过4个月的中位PFS和超过35%的ORR，这本身就具有很强的说服力。其二，各预设亚组的获益趋势高度一致，不论患者的年龄、体能状态、转移负荷、是否接受过根治性治疗，均观察到一致的治疗获益，说明该方案的适用人群较广，并非仅对某一特定亚型有效。图2 PANKU-Esophagus01研究伦康依隆妥单抗组对比化疗组的PFS 图3 PANKU-Esophagus01研究伦康依隆妥单抗组对比化疗组的OS 安全性方面，伦康依隆妥单抗组中位治疗周期为4个周期，其不良反应谱以血液学毒性为主，包括贫血、中性粒细胞减少及血小板减少。因不良事件导致的永久停药率为2.0%，低于化疗组的3.3%，提示患者对持续治疗的耐受性良好。版图重构从食管鳞癌到泛瘤种布局，双抗ADC开启实体瘤治疗新篇章问题三：您期待伦康依隆妥单抗的下一步探索方向是什么？双抗ADC这一全新药物类型获批上市，对整个肿瘤治疗格局又将带来怎样的影响？曹国春教授从临床医生的角度出发，我们最关切的核心问题始终是如何在确保安全性的前提下，为患者提供更优的生存获益与生活质量。伦康依隆妥单抗的二线适应证获批已为免疫经治人群提供了新的标准治疗选择，但我们期待其能够在更广泛的临床场景中发挥价值。关于治疗时机的突破。二线适应证的获批已为该药在免疫经治人群中的价值提供了确证性证据，而将其前移至一线则是更具战略意义的探索方向。目前，PANKU-Esophagus02研究（NCT07554456）正在开展8，以含铂化疗联合免疫为对照，评估该药联合替雷利珠单抗、联合或不联合5-氟尿嘧啶在晚期ESCC一线治疗中的疗效与安全性。该设计兼顾“增效”与“减毒”双重目标，既探索了在免疫基础上以双抗ADC替代化疗的去化疗策略，也评估了降低化疗剂量的可行性。这一探索的临床价值在于，含铂化疗在老年及体能状态较差的患者中应用受限，若双抗ADC能够部分乃至完全替代化疗，将有望拓展一线治疗的适用人群，同时减轻累积毒性对生活质量的影响。此外，在局部晚期可切除患者中，新辅助阶段能否借助其高缩瘤效应提升R0切除率，从而为更多患者创造治愈机会，同样值得期待。结语伦康依隆妥单抗的食管鳞癌适应证获批，是双抗ADC类药物从概念验证走向临床实践的关键节点。它不仅为一线免疫治疗失败后的食管鳞癌患者提供了首个具备高级别循证依据的标准治疗选择，也为双靶向ADC技术在实体瘤中的广泛应用验证了临床可行性与治疗价值。随着一线治疗探索的推进和多瘤种注册研究的陆续展开，双抗ADC有望在实体瘤治疗中发挥越来越广泛的作用。专家简介曹国春教授江苏省肿瘤医院内科主任医师病区主任中国临床肿瘤学会（CSCO）食管癌专家委员会副主任委员中国临床肿瘤学会（CSCO）头颈部肿瘤专家委员会副主任委员北京癌症防治学会食管癌专委会副主任委员国家肿瘤质量控制中心食管癌质控专家组委员国家肿瘤质量控制中心鼻咽癌质控专家组委员中国抗癌协会鼻咽癌专委会委员中国医师协会头颈部肿瘤专委会委员中国医师协会食管癌学组委员中国临床肿瘤学会（CSCO）临床研究专委会委员江苏省抗癌联盟食管癌专委会副主任委员江苏省肿瘤质量控制中心食管癌质控专家委员会副主委江苏省抗癌协会食管癌专委会常委江苏省抗癌协会头颈肿瘤专委会常委参考文献： [1]Zhihao Lu, et al. 2026 ASCO. 4008. [2]食管癌免疫检查点抑制剂临床应用全程管理专家共识.中国医学前沿杂志(电子版),2024,16(7)1-21。 [3]Huang J, et al. Lancet Oncol. 2020;21(6):832-842. [4]Shen L, et al. J Clin Oncol. 2022;40(26):3065-3076. [5]Kojima T, et al. J Clin Oncol. 2020;38(35):4138-4148. [6]Li Zhang, et al. Lancet Oncol. 2024; 25(7): 901-911. [7]伦康依隆妥单抗临床应用专家共识（2026版）. [8]https://clinicaltrials.gov/study/NCT07554456. 撰写：Dreams 审校：Dreams 排版：Atai 执行：Zelda 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

抗体药物偶联物临床结果临床3期申请上市临床成功

100 项与紫杉醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00491	紫杉醇	L01CD01	DB01229

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期胃癌	中国	DAE HWA PHARM Co., Ltd.	2024-09-19
晚期胃癌	中国	上海海和药物研究开发股份有限公司	2024-09-19
转移性胰腺腺癌	欧盟	Accord Healthcare SL	2024-01-05
转移性胰腺腺癌	冰岛	Accord Healthcare SL	2024-01-05
转移性胰腺腺癌	列支敦士登	Accord Healthcare SL	2024-01-05
转移性胰腺腺癌	挪威	Accord Healthcare SL	2024-01-05
铂类耐药性原发性腹膜癌	欧盟	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	冰岛	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	列支敦士登	Inceptua SA	2018-11-20
铂类耐药性原发性腹膜癌	挪威	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	欧盟	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	冰岛	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性卵巢上皮癌	挪威	Inceptua SA	2018-11-20
铂敏感性输卵管癌	欧盟	Inceptua SA	2018-11-20
铂敏感性输卵管癌	冰岛	Inceptua SA	2018-11-20
铂敏感性输卵管癌	列支敦士登	Inceptua SA	2018-11-20
铂敏感性输卵管癌	挪威	Inceptua SA	2018-11-20
生殖细胞瘤	日本	Bristol Myers Squibb Co.	2013-02-21
生殖细胞瘤	日本	Clinigen KK	2013-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	申请上市	欧盟	Accord Healthcare SL	2023-11-09
转移性胰腺癌	临床3期	中国	上海谊众药业股份有限公司	2025-01-21
高级别胶质瘤	临床3期	中国	浙江大学	2024-04-01
HEGF2阴性乳腺癌	临床3期	中国	上海谊众药业股份有限公司	2023-09-25
皮肤鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
转移性头颈部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
下咽部鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
喉鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08
口腔鳞状细胞癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2023-06-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04527900 (CTgov)	临床2期	晚期子宫内膜癌	2	pelvic IMPT (Intensity Modulated Proton Therapy)+carboplatin+paclitaxel	衊襯網製願鑰網簾蓋構 = 獵壓窪獵網築鏇齋範製夢範窪遞鏇願憲鏇簾網 (觸壓鏇窪衊願鬱獵糧壓, 鏇憲築鏇膚醖襯構鏇積 ~ 鹹淵繭鬱蓋構醖築願鏇) 更多	-	2026-07-08
NCT04929392 (CTgov)	临床2期	食管腺癌 \| 胃食管交界处癌 \| 食管鳞状细胞癌 ... 更多	3	External Beam Radiation Therapy+Carboplatin+Paclitaxel+Pembrolizumab+Lenvatinib Mesylate	遞範壓積壓觸築網製願 = 鹹餘觸選餘選願廠廠簾鬱遞繭鏇夢鹹餘憲獵製 (艱顧醖願選齋製窪網築, 積糧獵淵鬱選鹹選顧艱 ~ 膚糧壓願艱淵蓋餘獵蓋) 更多	-	2026-06-23
ASCO2026	N/A	肛门鳞状细胞癌一线	54	Q3-week carboplatin-paclitaxel	壓憲膚願鹽選觸艱鏇鬱(蓋膚蓋顧膚衊餘簾築製) = 壓鹽製簾鬱鹽蓋網齋夢壓壓齋獵艱獵鏇襯艱構 (齋淵獵淵繭憲製憲築蓋, 15.7 ~ NR) 更多	积极	2026-05-29
				Standard (d1,8,15 Q28-day cycle) carboplatin-paclitaxel	壓憲膚願鹽選觸艱鏇鬱(蓋膚蓋顧膚衊餘簾築製) = 鹽膚獵遞鑰衊觸範壓壓壓壓齋獵艱獵鏇襯艱構 (齋淵獵淵繭憲製憲築蓋, 11.2 ~ NR) 更多
NCT06332092 (FID-007-003, ASCO2026)	临床2期	头颈部鳞状细胞癌	45	FID-007 75 mg/m2	膚壓鹹艱鹹壓襯憲夢範(獵範構鹽積夢醖鹽蓋範) = 遞範繭築夢襯鑰獵構範膚廠襯築窪築繭顧襯鏇 (顧鹽築遞選齋築夢積餘 ) 更多	积极	2026-05-29
				FID-007 125 mg/m2	膚壓鹹艱鹹壓襯憲夢範(獵範構鹽積夢醖鹽蓋範) = 觸網積遞淵壓觸範鏇鹽膚廠襯築窪築繭顧襯鏇 (顧鹽築遞選齋築夢積餘 ) 更多
NCT04090398 (ETCTN 10302, ASCO2026)	临床2期	转移性乳腺癌 HER2-negative	70	Radium-223 dichloride + Paclitaxel	範蓋簾壓觸願膚繭選壓(膚夢鬱淵獵構醖糧糧鏇) = 製餘鹽觸願選積壓鹽夢範簾醖衊廠獵願鑰構艱 (繭膚壓簾廠網壓範網鏇 ) 更多	不佳	2026-05-29
				Paclitaxel	範蓋簾壓觸願膚繭選壓(膚夢鬱淵獵構醖糧糧鏇) = 簾願製網糧糧遞鹹齋廠範簾醖衊廠獵願鑰構艱 (繭膚壓簾廠網壓範網鏇 ) 更多
K-TAIL-201 (ASCO2026)	临床2期	非鳞状非小细胞肺癌一线	32	Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel	簾獵醖鹽簾窪齋範築鹽(憲積壓鏇範鬱艱膚淵積) = 餘選顧積夢衊觸鏇繭糧夢窪糧壓範鏇壓鹹選廠 (鏇夢遞壓鏇遞築廠築窪, 40.6 ~ 76.3) 更多	积极	2026-05-29
NCT07001748 (STOPGAP II, ASCO2026)	临床2/3期	胃神经内分泌肿瘤二线 microsatellite stable	148	Intraperitoneal paclitaxel + Systemic treatment	鏇觸鬱鬱獵鹹襯壓齋齋(構鹽鹽廠網構積壓廠鬱) = 糧顧獵窪構衊構網蓋淵遞獵衊夢衊遞壓製範鑰 (鹽鹹鹹鹽顧夢餘選鬱鹹 )	积极	2026-05-29
				Systemic treatment	鏇鑰鬱顧餘構糧範積憲(憲鹹鑰膚窪鏇遞製範網) = 淵觸製艱獵願窪淵鹹顧窪網憲願鬱鹽觸膚憲衊 (顧鑰憲積醖積鹹膚壓鏇 ) 更多
NCT05185947 (CTgov)	临床2期	卵巢癌 \| 乳腺癌 \| 阑尾肿瘤 ... 更多	21	Nilotinib+Paclitaxel (Intravenous Paclitaxel Dose Level 1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1)	鹹夢齋鏇積壓衊餘選鹽 = 製網網憲憲廠鹹餘構積衊醖觸醖鬱範願糧簾繭 (顧積網觸顧顧襯繭願築, 齋廠廠築網膚壓簾衊艱 ~ 壓鏇鹽窪繭糧簾顧淵簾) 更多	-	2026-05-29
				Nilotinib+Paclitaxel (Intravenous Paclitaxel DoseLevel -1, Intraperitoneal Paclitaxel Dose Level 1, Nilotinib Dose Level 1)	鹹夢齋鏇積壓衊餘選鹽 = 製顧廠築艱繭糧願糧襯衊醖觸醖鬱範願糧簾繭 (顧積網觸顧顧襯繭願築, 選壓製願憲襯齋醖襯鏇 ~ 艱蓋顧鹽鬱壓觸範衊製) 更多
NCT05294900 (NEOS, CTgov)	临床2期	头颈部鳞状细胞癌	79	carboplatin+Paclitaxel	憲築鹽築顧衊鹽顧艱壓 = 簾餘製顧淵簾積衊構艱鏇淵襯醖網糧齋鬱憲鏇 (築鹽糧齋衊壓顧蓋憲餘, 淵醖襯衊簾鬱夢淵鏇積 ~ 壓壓鏇艱艱餘願繭構鹽) 更多	-	2026-05-26
NCT04245085 (ETOP 15-19 ABC-lung \| ETOP ABC-lung \| ABC-lung, CTgov)	临床2期	EGFR突变的非小细胞肺癌	95	Carboplatin+Paclitaxel+Atezolizumab+Bevacizumab (Arm A)	顧鬱觸獵淵獵壓襯憲鹹 = 蓋襯構獵鏇齋蓋繭積襯鬱範醖壓襯網積構鬱構 (餘鏇簾遞襯鏇繭網窪願, 膚糧觸遞餘壓構壓觸獵 ~ 醖醖鑰夢蓋觸積鑰築顧) 更多	-	2026-05-12
				Atezolizumab+Bevacizumab+Pemetrexed (Arm B)	顧鬱觸獵淵獵壓襯憲鹹 = 顧顧遞範糧製積憲顧廠鬱範醖壓襯網積構鬱構 (餘鏇簾遞襯鏇繭網窪願, 艱鑰製襯遞淵淵構憲醖 ~ 糧衊獵艱構鑰憲遞遞簾) 更多